drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular immunotherapy (adoptive cell transfer)
drug_description
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting B-cell antigens (CD19 and/or CD22 for B-ALL/B-NHL or BCMA for multiple myeloma) and to co-express interleukin-15 (IL-15) to enhance T-cell activation, proliferation, survival, and persistence for antitumor cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are engineered to express a chimeric antigen receptor targeting B‑cell antigens (CD19 and/or CD22, or BCMA). Antigen engagement triggers CAR/CD3ζ signaling, leading to T‑cell activation and cytotoxic killing of tumor cells via perforin/granzymes and cytokine release. Co‑expressed IL‑15 delivers autocrine IL‑15R–JAK/STAT signaling that enhances T‑cell activation, proliferation, survival, and persistence, improving antitumor efficacy.
drug_name
Autologous CAR T cells co-expressing IL-15
nct_id_drug_ref
NCT06783816